The current immunotherapy strategy for breast cancer is limited. Tumor neoantigens have been proven to be a promising biomarker and potential target of immunotherapy in a variety of tumors. However, t
Cancer is subtyped according to the presence of certain features such as molecular markers. However, patients with similar levels of key molecular markers exhibit different levels of response or resis
DDX3XRNA helicase affects breast cancer cell cycle progression by regulating expression of KLF4 Ester Cannizzaro1, Andrew John Bannister1, Namshik Han, Andrej Alendar and Tony Kouzarides*. Gurdon Inst
